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Purpose: Inflammatory molecules have been demonstrated in the tear film of patients with severe dry eye disease (DED).
However, little attention has been paid to the most frequent moderate forms of DED. This study analyzes tear cytokine
levels and their clinical correlations in patients with moderate evaporative-type DED due to meibomian gland disease
(MGD).
Methods: Twenty three evaporative-type DED patients (46 eyes) of mild-to-moderate intensity and nine healthy subjects
(18 eyes) were recruited. Two symptom questionnaires were self-answered and multiple DED-related clinical tests were
performed. Unstimulated tears from each eye were isolated and were not pooled. Levels of 15 cytokines and chemokines
were measured by multiplex bead analysis, compared with control levels, and correlated with clinical tests.
Results: Fourteen out of the 15 molecules were reliably detected in 1 μl of unstimulated tears from DED patients.
Epidermal growth factor (EGF), fractalkine/CX3CL1, interleukin (IL) 1-receptor antagonist (Ra), IL-8/CXCL8, interferon
inducible protein (IP)-10/CXCL10, and vascular endothelial growth factor (VEGF) were found in 94%–100% of samples;
IL-6 in 65% (significantly more detected in older patients); IL-1β, interferon gamma (IFN-γ), and IL-10 in 30%–48%;
IL-17 in 13%; granulocyte macrophage colony stimulating factor (GM-CSF), IL-13, and tumor necrosis factor alpha (TNF-
α) in 2%–9%; and IL-5 was never detected. EGF, fractalkine/CX3CL1, IL-1Ra, IP-10/CXCL10, and VEGF levels were
significantly increased compared to normal controls. Pain was correlated with IL-6 and IL-8/CXCL8. Tear break-up time
correlated inversely with IL1-Ra. Schirmer test and tear lysozyme levels negatively correlated with IL-1Ra, IL-8/CXCL8,
fracktalkine/CX3CL1,  IL-6,  IP-10/CXCL10,  and  VEGF  had  the  same  tendency.  Conjunctival  staining  correlated
negatively with EGF and positively with IL-6.
Conclusions: In this sample of moderate evaporative-type DED patients, five inflammatory molecules were elevated.
Fracktalkine was demonstrated to be present and elevated in tears in human DED. IL-1Ra, IL-6, IL-8/CXCL8, and EGF
levels correlated with pain and with clinical parameters measuring tear stability, tear production or ocular surface integrity.
These results suggest that inflammation plays a role not only in severe DED but also in moderate evaporative DED.
Dry eye disease (DED) is a major and increasing health-
care problem due to its high prevalence and capacity to affect
patients’ quality of life, work-related issues, and health-care
resources  [1-3].  DED  was  recently  redefined  [4]  as  a
multifactorial  disease  of  the  tears  and  ocular  surface  that
results in symptoms of discomfort [5-7], visual disturbance
[8-10], and tear film instability [11-13] with potential damage
to  the  ocular  surface.  It  is  accompanied  by  increased
osmolarity of the tear film [14-17] and inflammation of the
ocular surface [18,19].
To  diagnose  DED,  a  combination  of  symptom
questionnaires and clinical tests is recommended [20]. These
clinical  tests  evaluate  tear  clearance  (production  and
elimination), tear stability, and ocular surface integrity. There
are some other more specialized tests that may eventually be
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introduced into clinical practice such as tear osmolarity [17],
conjunctival cytology [21], visual function [22], and confocal
microscopy [23]. It is universally recognized that symptoms
and clinical signs do not correlate well in DED, especially in
mild-to-moderate  forms  [6,24-29].  Therefore,  additional
clinical tests that demonstrate the presence of and characterize
the  type  of  inflammation  would  be  of  invaluable  help,
especially  if  those  tests  correlate  with  clinical  signs  and
symptoms. This would be a major advance in DED clinical
trials, where evaluation endpoints often fail to adequately
show therapy benefits, partially explaining the scarcity of
therapies for DED.
Increased levels of several inflammatory cytokines have
been correlated with clinical parameters in aqueous-deficient
DED  and  in  evaporative-type,  rosacea-related  DED  [18,
30-34]. Therefore, tear cytokine levels are already considered
as potential markers of inflammation in DED. However, the
majority of patients with DED have moderate forms of the
disease [35] for which studies are more limited and some have
failed to show increased levels of cytokines that were elevated
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862in more severe forms [36,37]. The aim of the present study
was to measure a wide panel of cytokines and chemokines in
tears from evaporative-type DED due to meibomian gland
disease (MGD) of moderate intensity. We then compared the
levels  of  these  inflammatory  mediators  with  controls  and
correlated the levels with clinical signs and symptoms.
METHODS
Patients and healthy controls: A total of 23 consecutive new
patients (7 males, 16 females; mean age ±standard deviation
[SD]  57.7±12.5  years,  range  28–79  years)  referred  to  the
University  of  Valladolid-IOBA  (Institute  of
OphthalmoBiology), Valladolid, Spain, for long-standing dry
eye-related symptoms were recruited. Inclusion criteria were
as follows: dry eye-related symptoms for at least the previous
12 months, no topical therapies other than artificial tears for
the previous 3 months, moderate intensity of symptoms as
defined by a score less than half of the total possible value on
the symptoms of discomfort questionnaire (SODQ) and the
Symptom Assessment in Dry Eye (SANDE) questionnaire.
Additionally, each prospective patient had a final diagnosis of
evaporative-type of DED due to MGD as defined by typical
lid  margin  changes  and  meibomian  secretion  alteration,
abnormal tear breakup time (TBUT), normal tests evaluating
tear  production,  and  mild-to-negative  vital  ocular  surface
staining. Exclusion criteria included any previous or present
ocular disease other than DED, surgery or contact lens wear,
any  systemic  disease  other  than  hypertension  or
hypercholesterolemia which was under control with no need
of drugs, such as systemic therapies including antihistamines,
anticholinergics,  antihipertensives  known  to  affect  tear
dynamics, or ocular therapies other than artificial tears. Nine
healthy volunteers (6 females and 3 males, mean age ±SD
33.1±8  years,  range  25–51  years)  constituted  the  control
group. These subjects were healthy, were not pregnant, were
not under any medication, had no previous or present history
of ophthalmic disease, did not have any ocular symptoms, and
were not contact lens users. These healthy volunteers had
Schirmer’s  test  1,  lysozyme  tear  levels,  corneal  and
conjunctival staining, and SODQ score within normal limits.
Written  consent  was  obtained  from  all  subjects  after
explanation of the nature and possible consequences of the
study. The study was approved by the University of Valladolid
Ethics Committee and followed the Tenets of the Declaration
of Helsinki.
Clinical Examination: Clinical evaluations were performed
following the sequence shown in Table 1. At least 10 min were
allowed between tests. Clinical evaluations were always done
by  authors  E.C.  and  M.C.  In  case  of  discrepancies  on
subjective tests, an agreement was reached by averaging the
score judged by each clinician. All tear samples were taken
by the same clinician (E.C.).
Dry  eye-related  symptomatology—Dry  eye-related
symptoms  were  evaluated  with  two  questionnaires.  The
SODQ included 8 questions, each one scoring from 0 to 4, to
yield  a  total  score  of  32  regarding  dryness,  sandy/gritty
feeling, burning/stinging, pain, itching, sensitivity to light,
and blurred vision [38]. The SANDE questionnaire evaluated
both dry eye intensity and frequency by using a 100 mm visual
analog scale [39].
TABLE 1. QUESTIONNAIRES AND CLINICAL TESTS FOR DRY EYE DISEASE (DED) PATIENTS.
Questionnaires and diagnostic tests (normal range or cut off point) Eye Mean±SEM
SODQ (0-32)   11.57±5.58
SANDE Severity (0-100); Intensity (0-100)   43.04±30.10; 48.78±37.41
Tear meniscus height (>0.3 mm) OD 1.90±0.80
  OS 1.90±0.80
Phenol red thread test (10 mm; 15 sec) OD 19.86±5.88
  OS 22.38±5.95
TBUT (>10 sec) OD 4.48±3.13
  OS 4.22±2.66
Corneal fluorescein staining (0-5) OD 0.83±1.79
  OS 0.81±1.77
Conjunctival rose bengal staining (0-5) OD 1.26±1.43
  OS 1.52±1.44
Tear lysozme (>1000 μg/ml) OD 2872.52±2783.10
  OS 3227.52±2239.95
Schirmer-1 test (>5 mm; 5 min) OD 16.70±8.44
  OS 17.35±8.86
Lid margin changes /Quality of meibomian gland secretion (0-4) OD 3.33±0.73
  OS 3.48±0.75
Questionnaires and tests were given in the order listed above. DED; Dry eye disease; SEM: standard error of the means; SODQ:
symptoms of discomfort questionnaire; SANDE: symptom assessment in Dry Eye; TBUT: tear breakup time; OD: right eye;
OS: left eye.
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863Tear sample collection—Tear collection was performed
before any other test and with a minimum of 10 min after the
patient  answered  the  two  symptom  questionnaires.
Unstimulated tear samples were collected non-traumatically
from the external canthus of open eyes, avoiding additional
tear reflex as much as possible. Glass capillary micropipettes
(Drummond, Broomall, PA) were used to collect 1 μl of tears.
Each sample was then diluted 1:10 in a sterile collection tube
containing  ice-cold  Beadlyte®  Cytokine  Assay  Buffer
(Upstate-Millipore, Watford, UK). Tubes with tear samples
were kept cold (4 °C) during collection, and stored at −80 °C
until assayed. The samples were obtained from right eye (OD)
and left eye (OS) of each individual, and were not pooled.
Tear production and stability—Tear production was
assessed  with  four  different  tests:  tear  meniscus  height
(TMH),  Schirmer’s  test,  phenol  red  thread  test,  and  tear
lysozyme level assay. TMH was measured after fluorescein
staining [40] using the slit lamp with a blue cobalt light. The
Schirmer-1 test [41] was performed by placing one sterile strip
(Schirmer Tear Test Strips, 5×35 mm; Alcon Laboratories,
Inc., Fort Worth, TX) in the lateral canthus of the inferior lid
margin of both eyes without topical anesthesia. Subjects were
asked to maintain their eyes closed during the test, and the
length of wetting was measured in millimeters after 5 min.
The phenol red thread test (Zone Quick Test; Menicon Ca,
Ltd., Nagoya, Japan) was achieved by placing the thread over
the  lateral  canthus  of  the  eye  and  read  after  15  s.  Tear
lysozyme  concentration  [42]  was  determined  by  the
Micrococcus  lysodeikticus  (ATCC  4698,  M3770;  Sigma-
Aldrich,  St.  Louis,  MO)  agar  diffusion  assay  in  Mueller
Hinton agar plates (Bio Merieux, Marcy l’Etoile, France). A
5-mm diameter Resma filter paper disc were gently applied to
the inferior conjunctival fornix of each eye for 1 min with eyes
closed. Samples were kept at 20 °C until processed. Each filter
paper was left in the plate with the Micrococcus lysodeikticus
inoculum (2×106 CFU/ml) suspension gel, and the inhibition
hallus was measured after 24 h. Lysozyme concentration was
calculated  from  a  standard  curve  of  the  inhibition  hallus
generated  with  several  concentrations  of  commercial
lysozyme (ATCC 4698, L6876; Sigma-Aldrich).
Tear  stability  was  evaluated  by  tear  break-up  time
(TBUT) test. Fluorescein strips previously wetted with 0.9%
sodium chloride were gently applied to the inferior fornix. The
time  lapse  between  instillation  of  fluorescein  and  the
appearance of the first randomly distributed dry spot was
measured  after  three  blinks,  and  the  mean  of  three
measurements was recorded [43].
Ocular  surface  integrity—Corneal  and  conjunctival
integrity were evaluated with fluorescein (Fluorets; Chauvin,
Aubenas,  France)  and  rose  Bengal  (Akorn,  Inc.,  Buffalo
Grove, IL) strips, respectively. Following the Oxford Scheme
(score 0–5) [44] for grading, corneal and conjunctival staining
were scored in each of the five different areas of the eye:
central,  inferior,  superior,  nasal,  and  temporal.  Total
fluorescein and total rose Bengal scores were calculated as the
sum of scores of each of the five areas.
Quality  of  meibomian  gland  secretion—Meibomian
gland function was evaluated last using the slit lamp. Lid
changes were recorded to aide in the diagnosis. However,
these were not further analyzed or used for correlations with
other data. The quality of meibomian secretion, determined
after expressing the glands, was judged as clear (0), cloudy
(1), granular (2), and solid (3) [45].
Analysis of cytokine/chemokine concentration: Cytokine and
chemokine levels in tear samples were determined by a 15×
multiplex  bead  analysis  (Linco-Millipore,  Watford,  UK)
using a Luminex IS-100 (Luminex Corp., Austin TX). This
kit  detects  free,  total,  and  non-degraded  forms  of  the
cytokines/chemokines  included.  Levels  of  interleukin
(IL)-1β,  IL-5,  IL-6,  IL-8/CXCL8,  IL-10,  IL-13,  IL-17,
interferon inducible protein (IP)-10/CXCL10, tumor necrosis
factor (TNF)-α, vascular endothelial growth factor (VEGF),
interferon  (IFN)-γ,  IL-1  receptor  antagonist  (IL-1Ra),
fractalkine/CX3CL1,  granulocyte-monocyte  colony
stimulating factor (GM-CSF), and epidermal growth factor
(EGF)  were  measured.  Ten  microliters  of  sample  were
incubated with antibody-coated capture beads for 2 h at 20 °C.
Washed beads were further incubated with biotin-labeled anti-
human  cytokine  antibodies,  followed  by  streptavidin-
phycoerythrin  incubation.  Standard  curves  of  known
concentrations of recombinant human cytokines were used to
convert fluorescence units to cytokine concentration (pg/ml).
Minimum  detectable  concentrations  (in  pg/ml)  were
IL-1β=0.19,  IL-1Ra=10.97,  IL-5=0.12,  IL-6=0.79,  IL-8/
CXCL8=0.32,  IL-10=0.41,  IL-13=4.06,  IL-17=0.25,
EGF=4.47, Fractalkine/CX3CL1=4.27, GM-CSF=0.23, IFN-
γ=0.55, IP-10/CXCL10=1.14, TNF-α=0.22, and VEGF=4.10.
Data were stored and analyzed using the Bead View Software
(Upstate-Millipore). Cytokine levels in control normal tears
were  determined  similarly,  by  using  a  22-plex  (Upstate-
Millipore),  and  a  7-plex  (Linco-Millipore)  cytokine/
chemokine  Luminex  commercial  assays  [46].  EGF,
fractalkine/CX3CL1,  IL-1Ra,  IP-10/CXCL10,  and  VEGF
levels were the only molecules that were determined using the
same reagents for both DED and control tears. Therefore, to
assure  identical  assay  results,  only  these  cytokines  and
chemokines were compared statistically between DED and
control subjects.
Statistical analysis: Data are presented as means±standard
error of the means (SEM), unless otherwise specified in the
text.  Statistics  were  analyzed  using  the  SPSS  software
package (SPSS 15.0 for Windows; SPSS, Chicago, IL) by a
licensed statistician (I.F.). The nonparametric Mann Withney
U test was used for comparisons of two independent sample
groups.  To  quantify  correlations  between  cytokine/
chemokine  levels  and  clinical  parameters,  the  Spearman
ranked correlation coefficient (rho) was determined along
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864with 95% confidence bands. Two-sided P-values of ≤0.05
were considered statistically significant.
RESULTS
Diagnostic  clinical  tests:  As  determined  by  the  selection
criteria,  the  patients  in  this  study  had  moderate  dry  eye
symptoms based upon the SODQ and SANDE questionnaire,
scoring less than 50% of the highest possible values (Table
1). A large panel of tests was given to exclude the possibility
that an aqueous-deficient component was contributing to the
disease, thus ensuring that DED for our patients could be
attributed only to an evaporative-component. Measurements
of tear meniscus height, Schirmer test, phenol red thread test,
and tear lysozyme concentration were all within normal limits,
confirming that these DED patients suffered predominantly
from evaporative loss of tears. Additionally, both corneal and
conjunctival staining scores were low, denoting little ocular
surface damage.
In  contrast,  TBUT  results  were  below  the  accepted
normal  limits  (Table  1)  denoting  tear  instability  due  to
excessive evaporation [47], the main consequence of MGD
on the tear film. Lid margin changes were consistent with
MGD and the quality of secretion was never normal. Based
upon results of the clinical examinations, all of the patients
were classified as having evaporative-type DED due to MGD
of mild-to-moderate intensity.
Tear  concentrations  of  cytokine  and  chemokines  in  DED
patients: Cytokine and chemokine levels were individually
measured in OD and OS tear samples of all patients. Of the
Figure 1. Cytokines and chemokines in
tears of DED patients. Fourteen out of
the  15  molecules  analyzed  were
detected.  EGF,  Fractalkine/CX3CL1,
IL-1Ra,  IP-10/CXCL10,  VEGF,  and
IL-8 were the more detected molecules
in evaporative-type DED tear samples
and were also the ones with the highest
concentration. Data are presented on a
logarithmic  scale  and  bars  represent
values for OS and OD together. Percents
of patients having detectable amounts
are shown at the top of each bar. EGF,
epidermal  growth  factor;  IFN-γ,
interferon  gamma;  GM-CSF,
granulocyte-macrophage  colony-
stimulating  factor;  IL,  interleukin;
IL-1Ra,  interleukin  1  receptor
antagonist; TNFα, tumor necrosis factor
alpha;  IP-10,  interferon  inducible
protein 10; VEGF, vascular endothelial
growth factor.
Figure 2. Comparison of tear cytokine/
chemokine levels in DED patients with
control  subjects.  EGF,  Fractalkine/
CXC3L1, IL-1Ra, IP-10/CXCL10, and
VEGF  levels  were  significantly
increased in evaporative-type DED tear
samples compared to controls. Values
are  presented  on  a  logarithmic  scale.
EGF,  epidermal  growth  factor;  IL,
interleukin;  IL-1Ra,  interleukin  1
receptor  antagonist;  IP-10,  interferon
inducible protein 10; VEGF, vascular
endothelial  growth  factor.  OD,  right
eye; OS, left eye. *p<0.05, DED tears
compared to corresponding controls.
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86515 molecules analyzed, EGF, fractalkine/CX3CL1, IL-1Ra,
and IP-10/CXCL10 were detected in all samples (Figure 1).
For IL-1Ra and IP-10/CXCL10, 52% and 74%, respectively,
of samples had values above the highest point of the standard
curve. In these two cases, we assigned the value as the highest
detectable  concentration  for  that  assay.  IL-8/CXCL8  and
VEGF were detected a 95.7% and a 93.5%, respectively. IL-6
was detected in 65% of samples, and IL-10 was detected in
48% of patients. The following cytokines and chemokines
were detected in 30% or fewer of the patients: IFN-γ (30%),
IL-1β (30%), IL-17 (13%), IL-13 (9%), GM-CSF (7%), and
TNFα (2%). IL-5 was the only molecule not detected in any
sample (Figure 1). All six of the most frequently detected
cytokines and chemokines were also the ones with the highest
concentrations.
EGF, fractalkine/CX3CL1, IL-1Ra, IP-10/CXCL10, and
VEGF levels in tears of DED patients were compared to
control tear levels determined in 9 healthy subjects (18 eyes).
Each of the molecules was significantly increased in the DED
patients compared to controls (Figure 2). IL8/CXCL8 and
IL-6 values in DED tears were similar to those found in control
tears, although we did not compare them statistically because
they were analyzed using different commercial kits. When
cytokine/chemokine  levels  between  OD  and  OS  were
compared, only for IL-6 was there a significant difference,
although the values were quite similar (OD: 209.9±56.6 pg/
ml; OS: 115.28±47 pg/ml; p=0.033).
Correlation analyses between tear cytokine/chemokine levels
and clinical signs and symptoms: We performed correlation
analyses between cytokine/chemokine levels and all signs and
symptoms for the seven molecules detected in more than 50%
of  DED  patients  (Figure  2):  EGF,  fractalkine/CX3CL1,
IL-1Ra,  IL-8/CXCL8,  IP-10/CXCL10,  VEGF,  and  IL-6.
Because  we  did  not  pool  tear  samples,  each  correlation
between the cytokine and chemokine levels and the signs and
symptoms maintained OD and OS laterality.
Correlation  with  age  and  gender—There  was  a
significant  positive  association  with  age  for  fractalkine/
CX3CL1 levels in OS (p=0.0019) and borderline significant
in OD (p=0.0573; Figure 3); IL-8/CXCL8 levels in both eyes
had the same tendency, almost reaching significance for OS
(p=0.09). Those patients for whom IL-6 was detected were
significantly older, 66±6 years than the 35% of patients for
whom IL-6 could not be detected, 53±3 years (p=0.05). There
were no significant correlations between cytokine/chemokine
levels and gender except for OD IL-8/CXCL8 levels being
significantly higher in males than females (p<0.05).
Correlation  with  symptoms—No  correlations  were
found between any molecule detected in tears with the global
scores  for  either  the  SODQ  or  SANDE  questionnaire.
However, some significant correlations were obtained when
Figure  3.  Fractalkine/CX3CL1  and
IL-8/CXCL8 levels correlation with age
in DED patients. Fractalkine/CX3CL1
and  IL-8/CXCL8  levels  correlated
positively with age in evaporative-type
DED  tear  samples.  Spearman  ranked
correlation  test  was  used  and  the
strength  of  correlation  between
variables  was  determined  by  the
Spearman's rho correlation coefficient.
Dotted  lines  indicate  the  95%
confidence bands. IL, interleukin; OD,
right eye; OS, left eye.
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866each of the items evaluated in SODQ questionnaire were
individually compared with cytokine levels. Thus, when pain
was  analyzed,  IL-6  and  IL-8/CXCL8  levels  in  OS  were
significantly higher in patients scoring 1 versus those scoring
0 or 2 (Figure 4). OD values had the same tendency, although
the correlations were not significant. IL-1Ra levels increased
with  pain  score  in  both  eyes  but  did  not  reach  statistical
significance (Figure 4). Regarding sandy/gritty feeling, for
IL-6 there was a tendency toward positive correlation but the
results were not statistically significant for either eye. IL-6
levels in OS also showed a tendency to correlate with blurred
vision (p=0.077), with higher levels for patients that scored
3–4 of the scale in which 4 is the maximum.
Each clinical diagnostic test was correlated with each of
the seven molecules detected in more than half of the moderate
DED patients’ tears. Only IL-1Ra, IL-8/CXCL8, fractalkine/
CX3CL1, and IL-6 showed statistical correlations or similar
relevant tendencies (Figure 5). In general, there was an inverse
relationship between the levels of IL-Ra, IL-6, IL-8/CXCL8
and fractalkine/CX3CL1 and the Schirmer test, lysozyme, and
TBUT values. IL-6 levels in both eyes correlated positively
with  rose  Bengal  staining,  but  only  significantly  for  OD
(Figure  5).  EGF  levels  were  positively  correlated  with
Schirmer and lysozyme tests, which measure tear production,
and negatively correlated with rose Bengal and fluorescein
staining, which measure ocular surface integrity (Figure 6).
However, except for the correlation of OS EGF levels with
rose  Bengal  staining  (p=0.0256),  none  of  these  reached
statistical significance.
DISCUSSION
In this study, we found that several cytokines and chemokines
were  increased  in  tears  from  evaporative-type  MDG-
dependent DED. These patients had mild-to-moderate signs
at the ocular surface with moderate-to-severe symptoms, and
there  were  some  correlations  between  the  inflammatory
mediators and the signs and symptoms. DED is a type of
ocular surface inflammation where signs and symptoms often
do not correlate well, particularly in the mild-to-moderate
cases  [6,24-29].  There  is  growing  interest  in  finding  a
potential  biomarker(s)  that  reflect  the  symptomatology  of
these patients. In the more severe forms of DED, the levels of
several cytokines and chemokines are increased [18,32-34,
48,49], and correlation studies revealed associations between
some  of  those  inflammatory  mediators  with  clinical
parameters [30,31]. Furthermore, increases in inflammatory
cytokine  tear  concentrations  may  be  responsible  for  the
irritation symptoms and ocular surface disease in DED [50].
However much less is known about the cytokine/chemokine
levels in those patients having mild-to-moderate DED. Those
patients are characterized by being highly symptomatic, but
without important clinical sign alterations.
Our  study  revealed  that  tears  from  mild-to-moderate
DED  patients  have  significantly  increased  levels  of  EGF,
fractalkine/CX3CL1, IL-1Ra, IP10/CXCL-10, IL-8/CXCL8,
and VEGF. Previous studies by others have shown that EGF
was decreased in tear fluid from Sjögren’s syndrome patients
[18], and also in those patients with DED but without MGD
[31]. However, Lam et al. [31] and Rao et al. [51] also showed
Figure 4. Correlation studies with SODQ pain score. IL-6 and IL-8/
CXCL8 were significantly increased for pain score 1 compared to
pain scores 0 and 2 (OS *p=0.003 for IL-6; *p=0.027 for IL-8/
CXCL8; OD p-values were not significant but followed the same
trend as OS). IL-1Ra levels increased with pain in both eyes but did
not reach statistical significance. IL, interleukin; OD, right eye; OS,
left eye.
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had higher EGF tear levels.
We previously have described the presence of fractalkine/
CX3CL1 in normal human tears [46], and to our knowledge,
this is the first report that describes increased levels of this
molecule in tears from DED patients. Fractalkine/CX3CL1
differs greatly from other chemokines in that it can exit the
cell either in a soluble form or in a membrane-bound form
[52]. It interacts with the unique receptor CX3CR1 that is
expressed on monocytes, natural killer cells, and some T cells.
Soluble fractalkine/CX3CL1 is a potent chemoattractant for
CX3CR1+  leukocytes.  Fractalkine/CX3CL1-CX3CR1
interaction  contributes  to  the  development  of  various
inflammatory diseases such as rheumatoid arthritis, asthma,
Wegener’s  granulomatosis,  Crohn’s  disease,  psoriasis,
glomerulonephritis,  experimental  autoimmune  anterior
uveitis, and atherosclerosis [52-57]. A role for fractalkine/
CX3CL1 in a mouse model of Sjögren syndrome has been
very recently proposed [19]. Its role in human dry eye is yet
unknown and deserves further analysis.
IL-1Ra levels were also significantly increased in tears
from  patients.  This  is  consistent  with  a  previous  report
showing that IL-1Ra concentration is increased in DED tear
fluid and in conjunctival cytology specimens from Sjögren’s
syndrome patients with aqueous tear deficiency [32]. It is
produced  by  corneal  epithelial  cells  and  fibroblasts  [58].
IL-1Ra is a naturally occurring cytokine receptor antagonist
[59,60]  that  serves  as  a  modulator  of  immune  responses
regulating  the  agonist  effects  of  IL-1  during  chronic
inflammatory and infectious diseases. IL-1Ra acts as a natural
anti-inflammatory  protein  in  arthritis,  colitis,  and
granulomatous pulmonary disease [59].
Tears from the DED patients had significantly increased
IP-10/CXCL10  levels.  This  molecule  is  a  potent
chemoattractant for activated Th1 and natural killer cells.
IP-10/ CXCL10 binds to cells through the CXCR3 receptor,
which is preferentially expressed in Th1 cells as well as in
eosinophils.  Significantly  increased  IP-10/CXCL10
expression in both corneal and conjunctival epithelium has
been described in an experimental animal model of dry eye
[61] and more recently in tears from Sjögren Syndrome DED
patients, and also, but non significantly, in non-Sjögren DED
patients  [51].  Human  conjunctival  epithelial  cells  in  vitro
secrete  significantly  increased  amounts  of  IP-10/CXCL10
when  stimulated  by  TNF-α  and  INF-γ  [62].  Increased
expression  of  this  molecule  also  occurs  in  some  human
chronic inflammatory diseases, as in the airways of subjects
with  chronic  obstructive  pulmonary  disease  [63]  and  in
patients with asthma [64,65], where the level is correlated with
lymphocyte number. Chemokines that preferentially attract
Th1 cells via the CXCR3 receptors, such as IP-10/CXCL10
or MIG/CXCL9, are involved in the polarization of T cell
recruitment as they concomitantly block the migration of Th2
cells in response to CCR3 ligands [66].
We also found that VEGF levels were increased in mild-
to-moderate DED patients. VEGF expression in conjunctival
biopsies  and  tears  are  increased  in  some  ocular  chronic
inflammatory diseases such as vernal keratoconjuntivitis or
atopic keratoconjuntivitis [67,68], where it plays a crucial role
in the remodeling process of these severe allergic conjunctival
disorders [68]. Conjunctival fibroblasts significantly increase
VEGF  mRNA  expression  under  the  effect  of  several
cytokines, such as TGF-β1, IL-1β, and IL-4 [69]. High levels
of  VEGF  immunoreactivity  also  occur  in  conjunctival
epithelial  cells  and  inflammatory  cells  in  vernal
keratoconjuntivitis biopsies [68]. Recent studies have also
shown that, in addition to its well known angiogenic role
[70], VEGF can also act as a direct proinflammatory mediator
during the pathogenesis of rheumatoid arthritis [71-74].
IL-6 has been described as one of the key molecules in
DED. This molecule is increased in the tears and conjunctival
epithelium  of  DED  patients  [18,30,31,33,34,49],  and  its
presence correlates with some clinical parameters in patients
with severe forms of DED [30,31,34]. For this reason it has
been suggested as a possible biomarker for DED. However,
in our study, it was detected in only 65% of the samples, and
the levels were not different from those found in controls.
Additionally, we could detect IL-1β or TNF-α (that have also
been described as increased in DED [30,32,34]) in only 30%
and 2%, respectively, of the patients. This could be related to
the  fact  that  the  patients  included  in  this  study  had
evaporative-type and not aqueous-tear deficient DED, with
mild clinical signs. This is in agreement with previous studies
in symptomatic, moderate dry eye patients, where there were
no increases in levels of IL-1β, IL-6, IL-8/CXCL8, GRO-b,
ICAM-1, TRAIL, or ephrin A5 in tear fluid [36]. Some of
these agents are substantially increased in severe DES. In
another  study  in  which  IL-1β,  IL-6,  and  pro-matrix
metalloproteinase  (MMP)-9  tear  levels  were  measured  in
patients with different types of ocular diseases, including a
group of 20 hyposecretive moderate dry eye patients, only
proMMP9 was significantly increased in DED patients [37].
Although  no  correlations  with  global  scores  for  the
SODQ and SANDE questionnaires were found for any of the
cytokines, significant differences existed for IL-6 and IL-8/
CXCL8 in association with pain sensation scores. Maximal
values of both IL-6 and IL-8/CXCL8 were related to pain
sensation score 1. Correlations of IL-6 levels with the gritty/
sandy sensation score and with the blurred vision scores of 3–
4  were  close  to  statistical  significance.  Lam  et  al.  [31]
proposed that IL-6 levels in tears of mild level 1 DED can be
related to inflammation-induced hyperalgesia, which may be
the cause for irritation symptoms in these patients. DED has
been referred to as a chronic pain syndrome. Pain is a very
centrally  mediated  phenomenon  and  is  expressed  very
differently in individuals. Therefore one would expect better
objective correlation with signs. Cytokines play a role in pain
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868and hyperalgesia by direct action upon nerve endings, ion
channels,  and  through  other  pain  mediators  [75].
Proinflamatory  cytokines  (i.e.,  IL-1β,  TNF-α,  IL-6,  IL-8/
CXCL8, and fractalkine/CX3CL1) are mostly algesic, while
the so-called anti-inflammatory ones (IL-10, IL-4) or cytokine
antagonists  (such  as  IL-1Ra)  have  analgesics  properties
[75-77]. An imbalance of pro- and anti-inflammatory cytokine
expression, rather than individual specific cytokine levels, is
of importance for individual pain susceptibility. Individual
cytokine profiles may be of diagnostic importance in chronic
pain states, and might guide the choice of treatment [75].
Although therapies with anti-cytokine agents are currently
used  effectively  for  the  treatment  of  inflammatory  pain
conditions,  inhibition  of  downstream  signaling  molecules
rather than particular cytokines has been proposed as a safer
therapy due to the pleiotropic and redundancy of the cytokine
system [78].
Our results also showed that fractalkine/CX3CL1, IL-6,
IL-8/CXCL8,  IL-1Ra,  and  VEGF  levels  were  inversely
correlated with Schirmer test results and lysozyme levels,
which  measure  tear  production.  Although  not  significant,
EGF levels were positively correlated with meniscus height,
Schirmer  test,  and  tear  lysozyme  levels  and  negatively
correlated with vital staining by fluorescein and rose Bengal,
which  demonstrate  ocular  surface  damage.  Although
statistical  significance  was  not  reached  in  all  these
correlations,  our  results  are  in  agreement  with  those
describing the negative correlation of IL-6 with Schirmer test
results [30]. We also found that IL-6 was positively correlated
with  rose  Bengal  staining  (in  both  eyes,  statistically
significant for OD) and with fluorescein staining (only for
OD). Thus, higher levels of this cytokine were associated with
more damage to the ocular surface. Similarly, Lam et al.
reported that Schirmer test scores were negatively correlated
Figure 5. Correlation of OD and OS tear cytokine/chemokine levels with corresponding OD and OS clinical measurements of tear production
and ocular surface integrity in DED patients. IL-1Ra, IL-8/CXCL8, and Fractalkine/CX3CL1 levels correlated negatively with tear production
tests, and IL-6 levels correlated positively with rose Bengal staining test (measuring ocular surface integrity). A: Schirmer test, B: lysozyme
levels, C: BUT, and D: Rose Bengal staining. Cytokine/chemokine values are expressed in pg/ml in a 100× (IL-1Ra, IL-8 and fractalkine) or
10× (IL-6) scale. Spearman's rho correlation coefficient was determined. Dotted lines indicate the 95% confidence bands. IL, interleukin;
IL-1Ra, interleukin 1 receptor antagonist; OD, right eye; OS, left eye.
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869with IL-6 and IL-8/CXCL8 and positively correlated with
EGF [31]. They also found that EGF levels were negatively
correlated with corneal fluorescein and conjunctival lissamine
green staining scores.
Except for IL-6, we found no significant differences in
cytokine levels between OD and OS eyes. However, we did
find differences between OS and OD when we correlated
cytokine levels with the clinical signs and symptoms for each
eye. This inconsistency between eyes probably relates to the
high variability for each of the clinical tests. Thus, pooling
collected tear samples between eyes may lead to erroneous
conclusions in both clinical and research applications.
In conclusion, we have shown that in this sample of mild-
to-moderate evaporative-type DED patients, where signs of
tear production were normal and vital staining failed to show
ocular surface damage, inflammatory mediators in tears were
a  more  sensitive  and  reliable  indicators  of  disease.
Additionally,  IL-1Ra,  IL-6,  CXCL8/IL-8  and  EGF  levels
correlated with pain and with clinical parameters measuring
tear stability, tear production, and ocular surface integrity. All
these results suggest that inflammation plays a role not only
in  severe  or  aqueous-deficient  DED  but  also  in  mild-to-
moderate evaporative DED due to MGD.
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